

More fake Avastin found in EU, thanks to FMD Scanning June, 2019



WHO warns of falsified versions of cancer drug Ponatinib February, 2019

PHOTOGRAPHS OF CONFIRMED FALSIFIED ICLUSIG PRODUCTS

1. ICLUSIG 45mg (30 tablets), Batch number PR072875



September, 2019

HSA Stops Supply of Eight Brands of Ranitidine Products in Singapore

Eight brands of ranitidine medicines have been found to contain trace amounts of a nitrosamine impurity, Nnitrosodimethylamine (NDMA), which are above the internationally acceptable level. As a precautionary measure, the Health Sciences Authority (HSA) is stopping the sale and supply of the affected ranitidine medicines at clinics, hospitals and pharmacies [see Table A for full list of medicines].

Kenyataan Akhbar KPK 29 Mac 2019 -Produk Losartan yang ditarik Balik di Singapura Serta Situasi di Pasaran Malaysia

BY DG OF HEALTH ON MARCH 29, 2019

Kenyataan akhbar ini dikeluarkan berikutan notis panggil balik oleh Health Sciences Authority (HSA), Singapura ke atas tiga (3) produk yang mengandungi losartan daripada sumber bahan aktif Hetero Labs Limited, India kerana kehadiran impuriti N-nitroso-N-methyl-4-aminobutyric acid (NMBA). Impuriti ini berkemungkinan boleh menyebabkan kanser kepada pengguna dalam jangka masa panjang. [...]



Pharmaceutical Serialization & Traceability



Track

Understand where an item is at any point in time



Trace

Understand where an item was at any point in time




Authenticate

Understand whether an item is **genuine** at any point in time


Global Serialization Standard for Pharmaceutical

assigning of a unique serial number to each saleable unit




The units can then be tracked through its entire supply chain — from production to retail distribution to the final dispensation to the patient

Global Pharmaceutical Serialization Regulations



Global Pharmaceutical Serialization Regulations





Non-compliance with global regulations results in ...

- Fines & Penalties
- Inability to sell product into global markets
- Reduction in product quality
- Inability to meet partner & customer expectations



And leads to negative business outcomes ...

- Reduced competitive advantage
- Lost revenues & market shares
- Negative impact on patient safety
- Damage to brand value & declining stock price

Selected Countries Experience

Country: Argentina

Primary Objective:

Combat against SF Medicines, safety of the supply chain, improvement of recall procedures, prevention of reimbursement fraud.

Regulated:

Yes (Reg. MS 435/11 and regulations supplementary thereto)

Date of Implementation:

First stage: December 15th, 2011

Data Carrier:

Free (linear barcode, 2D DataMatrix and RFID) on secondary packaging. The last five years evolution shows that, Datamatrix is preferred and used by most companies.

Database:

Within the NRA, with centralized information



Primary Objective:

Prevent the entry into the legal supply chain of falsified medicinal products

Regulated:

Yes (EU – Falsified Medicines Directive 2011)

Date of Implementation:

The system will be applicable from 9 February 2019 in the majority of the EU Member State

Data Carrier:

2D barcode (Data Matrix)

Database:

Delegated Regulation (EU) 2016/161 provides that the repositories system is set-up and managed by a non-profit legal entity or nonprofit legal entities



Selected Countries Experience

Country: India

Primary Objective:

Tracking & tracing of export consignment of pharmaceuticals.

Regulated:

Yes (Directorate General of Foreign Trade (DGFT))

Date of Implementation:

July 2014

Data Carrier:

2D Data Matrix

Database:

Centralised database, maintain by the government



Primary Objective:

Enable verification of the legitimacy of the drug product identifier down to the package level, enhance detection and notification of illegitimate products in the drug supply chain, and facilitate more efficient recalls of drug products.

Regulated:

Yes (Public Law 113-54, Title II, Drug Supply Chain Security Act) of 2013

Date of Implementation:

By November 27, 2023

Data Carrier:

The U.S. law currently specifies that the product identifier be a 2dimensional data matrix barcode for packages

Database:

Not determined yet



Selected Countries Experience

Country: Turkey

Primary Objective:

Reimbursement fraud, traceability.

Regulated:

Yes (Regulation Regarding the Packaging and Labeling of Medicinal Products for Human Use)

Date of Implementation:


July 2012

Data Carrier:

2D Data Matrix


Database:

Centralised database, develop, operate & maintain by the government



Approaches to the implementation

Presently there are 3 types of compliance requirements



Serialisation with reporting to a governmental database

In effect














Expected










Uploading serialised trade items into an institutional hub for verification

Enacted






Initially lot traceability – then full supply chain track & trace of serialised trade items

Enacted & partially in force



- Lot traceability in force
- Serialization required by 2017
- Full serialized track & trace by 2023



Why Track & Trace?



Strengthening Regulatory Activities through Global Standards



Cost Optimization & Operational Efficiency



Enhancing Ecosystem of Pharmaceutical Sector



Improve Patient Safety



Strengthening Regulatory Activities through Global Standards



2006

Malaysia National Medicines Policy (MNMP)

2014

Good Governance in Medicines (GGM)

2017

Pharmacy Programme
Strategic Planning
2017-2021



AS\$35B

Global value of counterfeit products

RM46M

Value of seized products in Malaysia in 2016

21K

Number of item of products seized in Malaysia in 2016

Substandard, and Falsified, Medicines

SF

Track & Trace system have been identified by WHO as one of the mechanism to fights SF



±20

Number of countries with track & trace regulations

AS\$1B

Results of Turkey's efforts have been tremendous, the nation is seeing savings of 1 billion US dollars annually



Cost Optimization & Increase Efficiency

RM 2.32B

MOH Malaysia budget for medicines, *consumables* and vaccine in 2018

Benefits to Healthcare Facilities

- Governance of more efficient and integral medicines management
- Reduce medicines waste
- Forecasting medicines use & trends
- Improve movement of drugs in supply chain e.g. product recalls/ disaster

Potential Benefits to Industries*

Value

Reduce inventory financing and holding cost

Reduce product waste due to obsolescence

Impact

\$11 million annual savings

\$4 million annual



Efficient product recall management and reduce cost of recalls \$3-12 million annual

15

* Strength In Unity, McKinsey & Company (2012)



value in 2015

Enhancing Ecosystem of Pharmaceutical Sector

I am also pleased to witness initiatives under the Healthcare NKEA bearing fruit as reflected by our results in **pharmaceutical exports** and healthcare travel this year. This had allowed the expansion of the healthcare industry which in turn helped **create job opportunities**, **expand the Gross National Income** and at the same time ensure healthcare remains affordable to the public.

Health Minister of Malaysia, 2016

RM 783Million Malaysia's pharmaceutical export Nalaysia's pharmaceutical export

The pharmaceuticals-related EPPs

contributed to consistent growth in export earnings from 2011 to 2016

T&T: Enhancing Ecosystem of Pharmaceutical Sector

Bolster the pharmaceutical export growth i.e. potential market: countries which have implemented track & trace regulations and opportunity to become CMO for global brand product.

Source: Annual Report 2016 National Transformation Plan



Improve Patient Safety



Minimizing Medication Error

Standard barcodes allows correct medication being serve for the correct patient



Product Authentication

More convenient for patient to identify genuine product by using mobile application



Access to Medicines Information


Improve patient adherence and knowledge on medicines



Product Traceability

Able to track the product endpoint for drug related issues (product recall etc)

Challenges In Pharmaceutical Supply Chain



Multichannel sales: growth in Over the counter and Traditional medicine through on-line web stores and corner shops

Visibility: Multiple steps in the supply chain with disrupted silo's of information

Demand-driven supply networks: Poor demand forecasting, stock outs with long lead times or over supply with drugs past expiry dates

Compliant distribution: Risk of noncompliance in warehouse and re-packing operations

Patient Outcome: challenge to have the right drug at the right time at the right quality reducing counterfeits

Track & Trace: Malaysian Perspectives

Objective: Patient Safety, Securing Supply Chain, Traceability & Visibility, Combat counterfeit & Unregistered Products

Scope



All registered product (A,X,T,N) *

*Implementation in phases

Packaging Levels



Saleable Unit Tertiary Packaging Aggregations

Data Carrier & Elements



GS1 2D DataMatrix


- GTIN
- Expiry date
- Lot/ batch number
- Serial Number

Database



Centralized Database (data own by government)

Reporting format: EPCIS



* Private: Hosp/Clinic Information System

Serialization at Production



Either directly on the unit or on a separate label



Every unit is scanned and checked



Barcodes are again checked when in bundle

Aggregations

GTINs to identify product along the along the packaging hierarchy.


To append batch/lot and serial numbers.

Providing «unique number» for secondary and higher packaging levels.





Packaging line changes



Level 5: **Network Level**

Network EPCIS

Authentication. exchange, Govt. Reporting

Mobile **Authentication** Network

Level 4: **Enterprise Level** **ERP**

Serial No. Manager

EPCIS Event Manager Enterprise

DC

Plant &

Level 3: Site Level Serialization Manager



Level 2: **Package Line Automation**



Level 1: **Devices** **Barcode Printer Code Reader RFID Reader Applicator**




Hardware

- Repository server
- Middleware server
- External gateway router (optional)
- ERP server (optional)
- Warehouse Mobile Solution
- Packaging Serialization Line
 - Pharmaproof print and vision inspection system for serialization code
 - Manual/Automated Aggregation
 - Thermal inkjet printer
 - Printer for aggregation to case and pallet.

Software

- Any track & trace System software available in the market
- Level 1 to Level 4

Track & Trace Dimensions to Drive Value Beyond Compliance



Improve efficiency in data management, good governance



Government

Minimizing diversions of product **Future** possibilities:

Reduce product waste due to obsolescence



Industries

Strengthening multiple stakeholders collaboration

Improving product recall efficiency and effectiveness

Improving

transaction accuracy/



Improve efficiency inventory assets & associated costs





Reducing medication errors; Patient safety

rotecting consumer & industries from **counterfeit** product

Patient/ Consumer

Drug Information, international trade rmation mprove

Thank You

Mohd Azuwan Bin Mohd Zubir
Pharmacy Policy & Strategic Planning
Ministry of Health Malaysia
mohdazuwan@moh.gov.my.